Home/CatalYm/Scott Clarke

SC

Scott Clarke

Chief Executive Officer

Therapeutic Areas

Oncology Immuno-oncology

CatalYm Pipeline

Drug	Indication	Phase
Visugromab (CTL-002)	Metastatic Non-squamous Non-Small Cell Lung Cancer (2nd line)	Phase 2b

Leadership Team at CatalYm

Clinton (Clint) Musil

Chief Financial Officer and Chief Business Officer

Chief Medical Officer

View full CatalYm profile